Yisheng BioPharma Completes $130 Million Series B Financing to Advance Global Commercialization of Innovative Vaccines

VCBeat (WeChat ID: vcbeat) has learned that Yisheng Biopharma Co., Ltd. (hereinafter referred to as “Yisheng Biopharma”) announced today the completion of its Series B financing round, raising over USD 130 million. The round was co-led by Oceanpine Capital and OrbiMed. Following the completion of this Series B financing, the company’s institutional investors include Oceanpine Capital, OrbiMed, STOA Capital, F-Prime Capital, 3W Fund, Hillhouse Capital, Adjuvant Capital, Magic Stone Alternative Investment, AIHC, Epiphron Capital, Superstring Capital, and Haitong Kaiyuan International, among others. The proceeds from this financing round will strongly support the construction of the company’s R&D center, advance multi-center clinical trials for multiple vaccine products in China and internationally, and facilitate the development of biological vaccine production facilities in China and Singapore, thereby accelerating the commercialization of its products. China Renaissance served as the exclusive financial advisor to the company in this Series B financing round.

Yisheng Biopharma is an international biopharmaceutical company headquartered in Beijing. Leveraging breakthroughs in its novel PIKA® immunomodulation technology, the company focuses on the research, development, and commercialization of innovative vaccines and biological products for antiviral and antitumor applications. It employs over 500 people across China, the United States, Singapore, and other countries and regions. Its YSJA™ (Yisheng Junan™) rabies vaccine is the first aluminum-adjuvant-free, freeze-dried rabies vaccine developed in China. The product has been commercialized in China, with more than 16 million doses administered.

The novel PIKA cell immunomodulatory technology platform is a proprietary immune activation technology independently developed by Yisheng Biopharma. It aims to modulate innate and adaptive immune responses by effectively regulating the TLR3, RIG-I, and MDA5 signaling pathways. Leveraging this platform, Yisheng Biopharma has developed multiple novel immunotherapeutic agents and innovative vaccine products, securing over 60 patents across more than 30 countries and regions. The lead candidate in development, the PIKA rabies vaccine, represents the emerging trend in next-generation rabies vaccines, designed to provide rapid post-exposure prophylaxis. This product has been classified as a novel vaccine by the World Health Organization (WHO) and listed as a therapeutic biological product by China’s National Medical Products Administration (NMPA). It is currently poised to enter Phase III international multicenter clinical trials.

Yisheng Biopharma’s other clinical-stage products currently under development include YS-ON-001 for the treatment of advanced solid tumors and the preventive hepatitis B vaccine YS-HBV-001. The company has recently expanded its pipeline with preclinical candidates such as the Pika recombinant protein COVID-19 vaccine (YS-SC2-010), YS-HBV-002 for the treatment of chronic hepatitis B, and YS-ON-002 for the treatment of advanced solid tumors.

Shao Hui, CEO of Yisheng Biopharmastated, “We are delighted to receive enthusiastic support from professional healthcare investors in this round of financing, which demonstrates that both our existing and new shareholders have full confidence in the company’s PIKA® immunomodulation technology, the sales performance of the Yisheng Junan rabies vaccine, and the market prospects of our innovative vaccine product pipeline. The renewed support and participation from investors will accelerate the development of our management and R&D teams, advance the progress of our product pipeline, and facilitate the construction of production facilities both domestically and internationally. The company remains committed to providing more advanced, safer, and more effective biological products to physicians and patients worldwide.”

As the lead investor in this round,Mr. Chen Liguang, CEO and Managing Partner of HaiSong Capitalstated: “The ongoing COVID-19 pandemic has significantly stimulated the development of the vaccine industry, which represents one of Haisong Capital’s key strategic focuses within the healthcare sector. Yisheng Biopharma is a biopharmaceutical company dedicated to technological innovation in immunomodulation and the research and development of vaccine products. Its founding team boasts extensive industry experience as well as expertise in vaccine R&D and commercialization. The company’s marketed rabies vaccine, Yisheng Junan, has demonstrated stable quality and strong market performance. Meanwhile, leveraging its proprietary PIKA technology platform, Yisheng Biopharma is developing multiple innovative vaccines featuring novel adjuvants, positioning itself with significant competitive advantages. We are highly optimistic about Yisheng Biopharma’s future growth. Haisong Capital is honored to serve as the lead investor in this funding round to support Yisheng Biopharma. We are delighted to grow alongside the company and its partners. This financing will accelerate Yisheng Biopharma’s journey toward becoming a globally leading biopharmaceutical company.”

Wang Ting, Managing Director of OrbiMed Asia Pacificstated: “China’s biotechnology industry is playing an increasingly prominent role in the global wave of innovation. As a long-standing shareholder of Yisheng Biopharma, we are delighted to once again support its R&D, clinical development, and industrialization efforts in vaccines and biopharmaceuticals worldwide, and we have full confidence in the execution capabilities of its management team.”

Zhang Xiao, Managing Director of China Renaissancestated: “We are honored to support the company’s Series B financing. The vaccine and biopharmaceutical sector has long been a key focus for investors, and Yisheng Biopharma is a scarce asset in the innovative vaccine and biopharmaceutical space. With its exceptional team, robust pipeline, and strong R&D and innovation capabilities, the company has earned the favor of numerous renowned institutions. We believe that the successful completion of this financing round will undoubtedly help the company achieve new breakthroughs and leaps forward on its journey to ‘prevent disease and safeguard health.’”

Yisheng Biopharma is a comprehensive international biopharmaceutical company headquartered in Beijing. Leveraging breakthroughs in its novel PIKA® immunomodulation technology, the company focuses on the research, development, and commercialization of innovative antiviral and antitumor vaccines and biological products. Yisheng Biopharma owns the globally unique PIKA vaccine adjuvant platform and has developed a portfolio of preventive and therapeutic vaccines, including those for rabies, hepatitis B, herpes zoster, influenza, and COVID-19. The company employs over 500 people across China, the United States, Singapore, and other countries and regions.

It is a professional investment management institution dedicated to long-term and value investing. It focuses on investing in high-tech and healthcare enterprises led by innovative technologies, particularly those with breakthrough and revolutionary innovations. By providing long-term, sustained support to outstanding entrepreneurs, complemented by international operational management expertise and extensive industry resources, it helps companies achieve rapid growth.

OrbiMed is dedicated to identifying and supporting biopharmaceutical and life sciences companies that advance human health. With approximately $13 billion in assets under management, OrbiMed has specialized in global healthcare investments for over two decades. Its investment portfolio spans biopharmaceuticals, life sciences technologies, medical devices, healthcare services, and diagnostics, covering stages from early-stage startups and growth-phase companies to mature enterprises and post-IPO entities. The investment team comprises more than 80 distinguished professionals worldwide, with expertise in life sciences, medicine, finance, and law.

Fidelity International’s private investment arm, F-Prime Capital (known in Chinese as Sidao Capital), is a global proprietary investment institution backed by the Fidelity Group. Leveraging its unique capital structure, F-Prime Capital flexibly deploys capital to support innovative companies in disrupting or leading their markets, helping entrepreneurs realize their ambitions. Currently, together with affiliated funds under the Fidelity Group, F-Prime Capital ranks among the top ten venture capital firms globally. Our global ecosystem continuously provides portfolio companies with access to an extensive talent pool and deep local expertise, facilitating their business growth. With over 25 years of venture capital experience in China, we have invested in more than 110 companies in the healthcare and technology innovation sectors. Over the past decade, we have invested nearly $6 billion in startups worldwide.

F-Prime Capital is a global venture capital firm backed by Fidelity Investments, focusing on investments in life sciences, healthcare, and high-tech industries. Since its establishment in 1969, F-Prime Capital has worked closely with entrepreneurs and academics in the healthcare and high-tech sectors to create new solutions. Website: www.fprimecapital.com.

3W Fund Management Limited (“3W Fund”) was established in 2012 and currently manages three US dollar-denominated funds. Its primary investors include major international institutional investors, such as sovereign wealth funds, university endowments, non-profit foundations, and family offices. 3W Fund focuses on fundamental, long-term investments in the Greater China region, concentrating on the TMT, biopharmaceuticals and medical devices, new energy and advanced materials, and consumer sectors, with the aim of achieving steady long-term capital appreciation. Since its inception, 3W Fund has cultivated an investment and research team with extensive expertise in equity investment and industry knowledge, continuously enhancing its organizational capabilities. The firm actively identifies and consistently invests in industry leaders and emerging growth companies, supporting corporate reform and innovation, and is committed to collaborating with entrepreneurs to achieve long-term, sustainable value investing.

Hillhouse, founded in 2005, is a firm dedicated to long-term structural value investing. After more than a decade of development, it has become one of the largest investment institutions in Asia. Hillhouse’s investment professionals possess extensive domestic and international investment experience, forming a perfect combination through complementary skills and strengths. Hillhouse’s investments span sectors including TMT, healthcare, consumer retail, enterprise services, and financial services, covering all stages of equity investment.

Adjuvant is a life sciences fund headquartered in New York, USA, dedicated to accelerating the development of new technologies to address the world’s most pressing public health challenges. Backed by prominent investors such as the International Finance Corporation, Novartis, and the Bill & Melinda Gates Foundation, Adjuvant identifies investment opportunities through a network comprising global scientists, public health experts, seasoned biopharmaceutical industry professionals, and financial specialists.

MSA Capital is a private equity investment firm deeply rooted in China with a global perspective, managing approximately USD 1.5 billion in assets. The capital under its stewardship primarily comes from leading global sovereign wealth funds, international asset management firms, pension funds, university endowments, funds of funds, family offices, as well as prominent Chinese entrepreneurs and leaders in the internet and biotechnology sectors.

MSA Capital has always focused on in-depth analysis and top-down research, possessing rich and profound insights and practical experience across all segments of the investment ecosystem. The firm has completed approximately 100 investments in the TMT and healthcare sectors. Headquartered in Beijing, China, MSA Capital maintains resident teams in the United States, the Middle East, Africa, and other regions.

AIHC Capital is a USD-denominated fund focused on global healthcare investment, dedicated to helping entrepreneurs and scientists address unmet clinical needs and enhance the efficiency of healthcare systems.

Epiphron Capital is a cross-border investment fund focused on the healthcare industry.

Superstring Capital Master Fund LP is an exempted limited partnership established in the Cayman Islands, operating as a private investment fund. It focuses on long-term fundamental investments in both public and private companies within the healthcare sector and is managed by Superstring Capital Management LP.

Haitong Kaiyuan International was initially established as the US dollar investment platform of Haitong Kaiyuan Investment Co., Ltd. Founded in 2008, Haitong Kaiyuan is a wholly-owned equity private investment platform of Haitong Securities. It focuses primarily on investment opportunities in technology-driven, state-supported sectors such as high-end manufacturing, information technology, and biopharmaceuticals. The firm manages assets exceeding RMB 30 billion and has cumulatively invested in more than 400 companies.

China Renaissance Capital Limited, established in 2000, is a leading Chinese investment bank and investment firm focused on the new economy and the upgrading and restructuring of traditional industries. Its core sectors include TMT, new consumption, and healthcare, supported by 19 specialized sub-sector teams across these three areas.